Dysregulated lactate metabolism synergizes with ALS genetic risk factors to accelerate motor decline
PLOS One · 2026
DOI: 10.1371/journal.pone.0347135 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Shweta Tendulkar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, United States of America. Hauptthemen laut MEDLINE: Lactic Acid, L-Lactate Dehydrogenase, Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIH.
Abstract (Originalsprache)
Neurons rely on glial ‘lactate shuttling’ for metabolic support, which declines with aging and in neurodegenerative disease. Full disruption of lactate shuttling in peripheral nerves causes progressive axon degeneration, but we were interested to understand how partial disruption, a scenario more relevant to aging and disease, contributes to neurodegeneration risk. Pyruvate and lactate are interconverted by lactate dehydrogenases (LDHA and LDHB) in both lactate producing and consuming cells. We therefore began by investigating Ldhb knockout mice (loss of LDHA, the dominant LDH in liver and muscle, caused embryonic lethality), and discovered that they develop progressive neuromuscular junction atrophy and functional decline without axon degeneration. Because even Ldhb + /- heterozygosity significantly affects motor behavior, we also wondered about a potential link to congenital disease and pursued this by identifying rare loss-of-function LDHB variants among ALS patients. Next, to better understand how LDHB loss leads to motor decline, we selectively deleted it in defined cell types. Schwann cell (SC)-specific deletion caused robust motor defects, whereas motor neuron–specific deletion has little effect. Reasoning that neuronal LDHB deficiency could model age-associated decline in lactate metabolism, we asked whether it would interact with ALS genetic risk. Indeed, motor-neuron LDHB deficiency synergizes with relatively mild ALS risk variants— TDP43 Q331K and Sod1 D83G knock-in alleles—to produce early motor neuropathy, indicating that LDHB loss enhances disease risk. These findings establish lactate metabolism as a modifier of motor system vulnerability and highlight it as a therapeutic target in peripheral as well as central neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
- Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, United States of America.
- Center for Advanced Oral Science, Niigata University, Niigata, Japan.
- Needleman Center for Neurometabolism and Axonal Therapeutics, St. Louis, Missouri, United States of America.
ORCID-Profile: Shweta Tendulkar, Amber R Hackett, A Joseph Bloom
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- NIH
Zitieren
APA
Tendulkar, S., Wu, T., Strickland, A., Hackett, A. R., Sato-Yamada, Y., Mao, X., Sasaki, Y., Milbrandt, J., Bloom, A. J., & DiAntonio, A. (2026). Dysregulated lactate metabolism synergizes with ALS genetic risk factors to accelerate motor decline. PLOS One. https://doi.org/10.1371/journal.pone.0347135
Vancouver
Tendulkar S, Wu T, Strickland A, Hackett AR, Sato-Yamada Y, Mao X, et al. Dysregulated lactate metabolism synergizes with ALS genetic risk factors to accelerate motor decline. PLOS One. 2026. doi:10.1371/journal.pone.0347135
BibTeX
@article{Tendulkar2026,
author = {Tendulkar, Shweta and Wu, Tong and Strickland, Amy and Hackett, Amber R and Sato-Yamada, Yurie and Mao, Xianrong and Sasaki, Yo and Milbrandt, Jeffrey and Bloom, A Joseph and DiAntonio, Aaron},
title = {Dysregulated lactate metabolism synergizes with ALS genetic risk factors to accelerate motor decline},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0347135}
}
EUVIMED